About

USPTO Denies Magnolia IPR After District Court Loss, Citing No “Second Bite”

Published
Score
10

Why it matters

On May 14, 2026, the USPTO Director issued a precedential decision denying institution of an inter partes review petition filed by Magnolia Medical Technologies against Kurin, Inc. over U.S. Patent No. 12,138,052 B1 (IPR2026-00097). The core holding reframes the purpose of AIA review: it exists as a quick, cost-effective alternative to district court litigation, not as a second opportunity for parties who have already litigated validity issues and lost.

Magnolia had challenged the patent in district court on anticipation and obviousness grounds but lost after its expert was precluded from offering opinions on those theories. The company then filed an IPR petition raising substantially the same invalidity arguments. The Director rejected Magnolia's position that the lack of a jury verdict on those specific theories justified reopening the dispute at the USPTO.

The precedential nature of this decision signals a tighter standard for discretionary denial when an IPR follows rather than replaces district court litigation. Patent owners facing post-trial IPR petitions now have concrete authority to cite when opposing institution, particularly where a petitioner already had a full opportunity to litigate validity in court. Petitioners should expect heightened scrutiny when seeking IPR review of claims already tested in litigation, even if procedural rulings limited the scope of evidence presented at trial.

mail Subscribe to Intellectual Property email updates

Primary sources. No fluff. Straight to your inbox.

Also on LawSnap